A brief Introduction of Beijing Sunho

          Founded in 2000, Beijing Sunho Pharmaceutical Co., Ltd. has an asset of nearly 1.8 billion yuan and 800+ employees. Sunho has four production bases, two in Beijing, one in Nanjing and one in Zhongshan, and branches in the United States, Europe and Hong Kong, China. Sunho (stock code: 920017) is a national high-tech enterprise that undertakes many national technology and industrialization projects, and has obtained national project supports from the Ministry of Industry and Information Technology, the Ministry of Science and Technology, and the National Development and Reform Commission for many times. Among them, the industrialized CMC/CDMO public service platform jointly built with the Shanghai Institute of Material Medical, Chinese Academy of Sciences, has received special support for biomedical contract R&D and production service platform construction, marking the beginning of Sunho's entry into the national team of pharmaceutical industrialization services.

         Sunho focuses on providing validation batch and registration batch productions, global application and commercial production services for new and generic drugs, and is committed to providing the global pharmaceutical industry with customized R&D and production services required for the full life-cycle of drug products from early clinical research to marketing.

          With the accumulation of drug R&D technology and industrialization experience, Sunho has formed a multi-core advantage represented by sustained-release preparation technology, immediate-release OTD technology and complex injection intelligent manufacturing technology, and high-end formulation in cartridges and pre-filled syringes. Currently, 9 GMP-compliant workshops have been built, containing 19 production lines, covering diverse dosage forms such as SVP, freeze-dried powder for injection, conventional tablets, freeze-dried OTDs, and capsules. The workshop producing SVPs (terminally sterilized vial and ampoule lines) has obtained the EMA certification (Germany and Poland), and the workshop producing SVPs and freeze-dried powder for injection (oncology drugs) has passed the US FDA inspection, providing the highest standard of compliance for global registration and launch of your products. The entire production process is data-driven through systems such as MES and LIMS, providing solid data support.

         In recent years, Sunho has provided CMC/CMO services for more than 130 pharmaceutical companies, including 50+ new drugs. And nowadays, Sunho has become more thoughtful in its service concept, more professional in its service approaches, more efficient in service delivery and more comprehensive in its service value!

         With the corporate culture concept of “Self-surpassing and Co-Development”, driven by technological innovation and with the mission of advancing China’s new drug innovation services to world-class standards, we are committed to building and sharing an internationally recognized, high-end CMC/CDMO service platform from China.